<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01038947</url>
  </required_header>
  <id_info>
    <org_study_id>ENZ-102</org_study_id>
    <nct_id>NCT01038947</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Intramuscular Uricase-PEG 20</brief_title>
  <official_title>A Cohort Dose-Escalation Phase 1 Study of Intramuscular Injection of Uricase-PEG 20</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EnzymeRx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EnzymeRx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, pharmacokinetics and pharmacodynamics of
      single and multiple intramuscular doses of Uricase-PEG 20
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uricase is an enzyme (found in most mammals but not humans) that converts poorly soluble uric
      acid into highly soluble allantoin. Because humans lack uricase, they are prone to develop
      elevated levels of uric acid, which can form crystals in the joints and soft tissues. In
      those which chronically elevated uric acid, gout may develop. In the setting of acute rises
      in uric acid, seen for example in tumor lysis syndrome, uric acid crystals can damage the
      renal tubules. Uricase-PEG 20 is a recombinant uricase conjugated with multiple PEG molecules
      designed to prolong the half-life and decrease the immunogenicity of uricase. This study will
      characterize the safety, pharmacokinetics and pharmacodynamics of intramuscular Uricase-PEG
      20, the anticipated route of administration to be used in future clinical development in
      gout.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">May 2010</completion_date>
  <primary_completion_date type="Anticipated">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (assessment of signs and symptoms and clinical laboratory measurements following administration of Uricase-PEG 20, graded according to the Common Toxicity Criteria for Rheumatology, version 2.0)</measure>
    <time_frame>Up to 35 days after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Uricase-PEG 20 serum concentration)</measure>
    <time_frame>Up to 35 days after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (plasma uric acid concentration)</measure>
    <time_frame>Up to 35 days after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Up to 35 days after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Gout</condition>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>Uricase-PEG 20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts will receive ascending doses of Uricase-PEG 20 in a sequential manner. The study will enroll both single dose cohorts and multi-dose cohorts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Uricase-PEG 20</intervention_name>
    <description>Intramuscular injection of Uricase-PEG 20 without premedication</description>
    <arm_group_label>Uricase-PEG 20</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Serum uric acid &gt; 6 mg/dL (men) or &gt; 5 mg/dL (women)

          -  Clinical laboratory values within normal limits or not clinically significant

          -  Women should be menopausal or peri-menopausal

        Exclusion Criteria:

          -  Prior exposure to uricase

          -  History of severe allergic reactions, or any allergy to PEG or pegylated products

          -  G6PD or catalase deficiency

          -  Medical condition that may interfere with ability to complete the study (e.g.,
             uncontrolled diabetes or hypertension, congestive heart failure NYHA Class III or IV,
             history of myocardial infarction, immunosuppression, pregnancy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony S Fiorino, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>EnzymeRx, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia Pardo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MRA Clinical Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rocelle Flores</last_name>
    <phone>201-843-4424</phone>
    <phone_ext>203</phone_ext>
    <email>rflores@enzymerx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MRA Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivian Rosales</last_name>
      <phone>305-772-2857</phone>
      <email>vrosales@miamiresearch.com</email>
    </contact>
    <investigator>
      <last_name>Patricia Pardo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Kivitz</last_name>
      <phone>814-693-0300</phone>
      <phone_ext>224</phone_ext>
    </contact>
    <investigator>
      <last_name>Alan J Kivitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.enzymerx.com</url>
    <description>Homepage of sponsoring company</description>
  </link>
  <reference>
    <citation>Bomalaski JS, Holtsberg FW, Ensor CM, Clark MA. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J Rheumatol. 2002 Sep;29(9):1942-9.</citation>
    <PMID>12233890</PMID>
  </reference>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2009</study_first_submitted>
  <study_first_submitted_qc>December 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2009</study_first_posted>
  <last_update_submitted>December 22, 2009</last_update_submitted>
  <last_update_submitted_qc>December 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>Anthony Fiorino, MD, PhD</name_title>
    <organization>EnzymeRx, LLC</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rasburicase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

